Of more than 100 compounds synthesized and tested for TGR inhibition (a more thorough description of compound design will form the basis of a future manuscript), the most promising were selected to be extensively characterized in the in vitro and in vivo studies described below
the composition comprises a cannabinoid selected from the group consisting of cannabidiol (CBD), Cannabinol (CBN), Cannabigerol (CBG), Cannabichromene (CBC), Cannabicyclol (CBL), Cannabivarin (CBV), Tetrahydrocannabivarin (THCV), Cannabidivarin (CBDV), Cannabichromevarin (CBCV), Cannabigerovarin (CBGV), Cannabigerol Monomethyl Ether (CBGM), Tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), tetrahydrocannabinolic acid (THCA), Cannabichromenic acid (CBCA), cannabigerolic acid (CBGA), tetrahydrocannabivari the antioxidant is selected from the group consisting of: L-ergothioneine, butylated hydroxytolune (BHT), butylated hydroxy anisole (BHA), tert-Butylhydroquinone (TBHQ), pyrogallol, propylgallate, N,N-Di-sec-butyl-p- phenylenediamine, coenzyme Q10, astaxanthin, ellagic acid, picrocrocin, lycopene, lutein/zeaxanthin, lutein, zeaxanthin, quercetin, vitamin C, IP-6, beta-carotene, epicatechin, ECGC-epigallocatechin gallate, safranal, proanthocyanidins, resveratrol, vitamin E, melatonin, and mitoQ
The unique anatomy of the nose-brain interface facilitates direct drug transport via the olfactory and trigeminal pathways to the brain, bypassing the bloodbrain barrier
This mechanism relies on intact pituitary and hypothalamic function, making efficacy dependent on baseline hormonal reserve and individual receptor sensitivity
Biochemical modulators of tight junctions (TJs): Occludin, Claudin-2 and Zonulin as biomarkers of intestinal barrier leakage in the diagnosis and assessment of inflammatory bowel disease progression
